CRP and rheumatoid arthritis: Similarly, a 2024 real-world study of filgotinib administered to 126 patients with RA revealed an improvement in symptoms at six months (patient global assessment, examiner global assessment, visual analog scale, DAS28-CRP, and CRP), with low activity in 37.2% and remission in 10.7%.